🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
JNJ
NYSE
🇺🇸 US
Johnson & Johnson
Healthcare
22Score
DipBuster Score™
$250.61
+$1.79 (+0.72%)
Live price · Source: Yahoo
52-Week Position
$164.23
82% of range
$269.43
Beta
0.235
Low vol
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.235
52W High$269.43
52W Low$164.23
DipBuster Brief
Key signals at a glance
Zone: Consider Trimming
Bearish
Near 52-Week High — Asymmetric Risk
At 82% of its annual range the stock is close to its peak. New buyers face limited upside and meaningful downside if sentiment shifts.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position82% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.235
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Johnson & Johnson (JNJ), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-06-11 | Wengel Kathryn E | SELL | 10,000 |
| 2026-06-11 | Wengel Kathryn E | SELL | 10,000 |
| 2026-06-11 | Wengel Kathryn E | BUY | 10,000 |
| 2026-06-09 | Woods Eugene A. | BUY | 161 |
| 2026-06-09 | Pinto Daniel E | BUY | 134 |
| 2026-06-09 | Hewson Marillyn A | BUY | 215 |
| 2026-05-01 | Reed John C | SELL | 25,255 |
| 2026-05-01 | Reed John C | SELL | 11,002 |
| 2026-05-01 | Reed John C | BUY | 25,255 |
| 2026-04-23 | West Nadja | BUY | 975 |
Valuation
P/E RatioN/A
Market CapN/A
Beta0.235
Dividend/yrNone
52W High$269.43
52W Low$164.23
52-Week Range
$164.23Now$269.43
82% through annual range
From 52W High−7%
From 52W Low+52.6%
📖 Plain English Summary
Johnson & Johnson is at 82% of its 52-week range. Beta 0.235 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for JNJ
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — JNJ
Heuristic · balance sheet, insider filings, price data, academic research
Johnson & Johnson — DipBuster Score 22/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Johnson & Johnson free
Add JNJ to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Trading 212
Commission-free investing. ISA and GIA available. FCA regulated.
Free share worth up to £100 when you sign up
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
7/25
Momentum & Volume
10/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
0
/100 · NEUTRAL
dip depth
0/25
oversold rsi
0/25
mean reversion
0/15
insider zone
0/25
capitulation
0/10
Insiders' avg buy price: $206.15 — marked 🟡 on the chart above.
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 22/100
📊
Run a full check in the AI analysis tab for a deeper look.
Company Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovat…
Sector
Healthcare
Market
🇺🇸 US
CEO
Joaquin Duato
Staff
141,700 employees
Website